Corient Private Wealth LLC Acquires 6,287 Shares of Biogen Inc. $BIIB

Corient Private Wealth LLC raised its holdings in Biogen Inc. (NASDAQ:BIIB) by 18.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 41,149 shares of the biotechnology company’s stock after purchasing an additional 6,287 shares during the period. Corient Private Wealth LLC’s holdings in Biogen were worth $7,245,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of BIIB. Reflection Asset Management bought a new stake in Biogen during the 4th quarter valued at $25,000. WPG Advisers LLC boosted its holdings in shares of Biogen by 417.9% in the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 117 shares during the period. First Horizon Corp bought a new position in shares of Biogen in the fourth quarter worth $30,000. Root Financial Partners LLC grew its position in shares of Biogen by 198.4% in the fourth quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 123 shares in the last quarter. Finally, MV Capital Management Inc. purchased a new position in shares of Biogen in the fourth quarter valued at $34,000. Institutional investors own 87.93% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on BIIB. Cantor Fitzgerald reissued an “overweight” rating on shares of Biogen in a report on Monday. Citigroup raised their target price on Biogen from $190.00 to $200.00 and gave the stock a “neutral” rating in a research note on Friday, May 1st. UBS Group raised Biogen from a “neutral” rating to a “buy” rating and lifted their target price for the company from $185.00 to $225.00 in a report on Wednesday, April 22nd. HSBC upped their price target on Biogen from $143.00 to $150.00 and gave the company a “reduce” rating in a research report on Tuesday, March 17th. Finally, Weiss Ratings upgraded shares of Biogen from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $217.37.

Biogen Price Performance

Shares of Biogen stock opened at $201.96 on Friday. The firm has a market capitalization of $29.82 billion, a PE ratio of 21.67 and a beta of 0.20. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34. Biogen Inc. has a 12 month low of $121.05 and a 12 month high of $206.67. The business’s 50-day moving average price is $192.66 and its 200-day moving average price is $185.46.

Biogen (NASDAQ:BIIB) last released its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, topping analysts’ consensus estimates of $2.95 by $0.62. The company had revenue of $2.48 billion during the quarter, compared to the consensus estimate of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.Biogen’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Sell-side analysts forecast that Biogen Inc. will post 13.95 EPS for the current fiscal year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.